标题
Synthetic lethality: the road to novel therapies for breast cancer
作者
关键词
-
出版物
ENDOCRINE-RELATED CANCER
Volume 23, Issue 10, Pages T39-T55
出版商
Bioscientifica
发表日期
2016-08-16
DOI
10.1530/erc-16-0228
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The BRCA1- 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
- (2016) Y. Wang et al. CANCER RESEARCH
- BRCA1 loses the ring but lords over resistance
- (2016) Simon N. Powell JOURNAL OF CLINICAL INVESTIGATION
- RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance
- (2016) Yifan Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
- (2016) Rinske Drost et al. JOURNAL OF CLINICAL INVESTIGATION
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes
- (2016) David W Morgens et al. NATURE BIOTECHNOLOGY
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
- (2015) Christopher J. Lord et al. Annual Review of Medicine
- PARP inhibitors in the management of breast cancer: current data and future prospects
- (2015) Luca Livraghi et al. BMC Medicine
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
- (2015) Giovanni Ciriello et al. CELL
- Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer
- (2015) Michael D. Brooks et al. Cell Stem Cell
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- The spliceosome is a therapeutic vulnerability in MYC-driven cancer
- (2015) Tiffany Y.-T. Hsu et al. NATURE
- Toward understanding and exploiting tumor heterogeneity
- (2015) Ash A Alizadeh et al. NATURE MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification and characterization of essential genes in the human genome
- (2015) T. Wang et al. SCIENCE
- Assessing the Role of Platinum Agents in Aggressive Breast Cancers
- (2015) William M. Sikov Current Oncology Reports
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
- (2015) T. Higuchi et al. Cancer Immunology Research
- BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance
- (2014) J. E. Jaspers et al. CANCER RESEARCH
- Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
- (2014) Luke A. Gilbert et al. CELL
- Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
- (2014) Poorval M. Joshi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- "The Race" to Clone BRCA1
- (2014) M.-C. King SCIENCE
- BRCA1 haploinsufficiency for replication stress suppression in primary cells
- (2014) Shailja Pathania et al. Nature Communications
- Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype
- (2014) Sarah L. Sawyer et al. Cancer Discovery
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors
- (2013) Brooke M. Emerling et al. CELL
- Fanconi anaemia,BRCA2mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling
- (2013) Stefan Meyer et al. JOURNAL OF MEDICAL GENETICS
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase
- (2013) T. R. Mereniuk et al. MOLECULAR CANCER THERAPEUTICS
- Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
- (2013) Nicolai Juul Birkbak et al. PLoS One
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo
- (2013) Sandra Morandell et al. Cell Reports
- A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2
- (2012) Katharina Schlacher et al. CANCER CELL
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells
- (2012) S Origanti et al. ONCOGENE
- NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells
- (2012) Ana M. Mendes-Pereira et al. PLoS One
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
- (2012) Susan M. Domchek et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
- (2011) P. M. L. H. Vencken et al. ANNALS OF ONCOLOGY
- BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance
- (2011) Rinske Drost et al. CANCER CELL
- Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11
- (2011) Katharina Schlacher et al. CELL
- The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
- (2011) D. Blazek et al. GENES & DEVELOPMENT
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- Stumbling Blocks on the Path to Personalized Medicine in Breast Cancer: The Case of PARP Inhibitors for BRCA1/2 -Associated Cancers
- (2011) Judith Balmaña et al. Cancer Discovery
- PALB2/FANCN: Recombining Cancer and Fanconi Anemia
- (2010) M. Tischkowitz et al. CANCER RESEARCH
- Secondary mutations of BRCA1/2 and drug resistance
- (2010) Kiranjit K. Dhillon et al. CANCER SCIENCE
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- Collaboration and competition between DNA double-strand break repair pathways
- (2010) Elizabeth M. Kass et al. FEBS LETTERS
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- A Genome-wide Camptothecin Sensitivity Screen Identifies a Mammalian MMS22L-NFKBIL2 Complex Required for Genomic Stability
- (2010) Brenda C. O'Connell et al. MOLECULAR CELL
- BRCA mutations in the management of breast cancer: the state of the art
- (2010) Steven A. Narod Nature Reviews Clinical Oncology
- Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
- (2010) Mary Ellen Moynahan et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
- (2010) Peter Bouwman et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Toward a unified nomenclature for mammalian ADP-ribosyltransferases
- (2010) Michael O. Hottiger et al. TRENDS IN BIOCHEMICAL SCIENCES
- Subtypes of familial breast tumours revealed by expression and copy number profiling
- (2009) Nic Waddell et al. BREAST CANCER RESEARCH AND TREATMENT
- Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma
- (2009) W. Sakai et al. CANCER RESEARCH
- PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response
- (2009) Feng Zhang et al. CURRENT BIOLOGY
- PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2
- (2009) F. Zhang et al. MOLECULAR CANCER RESEARCH
- A Selective Requirement for 53BP1 in the Biological Response to Genomic Instability Induced by Brca1 Deficiency
- (2009) Liu Cao et al. MOLECULAR CELL
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- PALB2 is an integral component of the BRCA complex required for homologous recombination repair
- (2009) S. M. H. Sy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance
- (2008) E. M. Swisher et al. CANCER RESEARCH
- Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
- (2008) B. Evers et al. CLINICAL CANCER RESEARCH
- ‘Triple Negative’ Breast Cancer: a New Area for Phase III Breast Cancer Clinical Trials
- (2008) L.S. Kilburn CLINICAL ONCOLOGY
- Cell Cycle-dependent Complex Formation of BRCA1·CtIP·MRN Is Important for DNA Double-strand Break Repair
- (2008) Longchuan Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations
- (2008) David S.P. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effect ofBRCA1/2Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer
- (2007) Angela Chetrit et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More